Alexion cautiously steps over to the C6 pathway with an early-stage development deal tied to buyout option
After building up its expertise in the C5 complement pathway through its work on Soliris, Alexion $ALXN is now on a low-budget journey to see what an upstart biotech can do with C6. And if it looks good, Alexion says it has an option to buy them out.
The biotech is Complement Pharma, which is now partnering with Alexion on the preclinical C6 complement inhibitor CP010. The drug has potential in a variety of neurodegenerative conditions, Alexion’s top researcher John Orloff says, and they’re paying up to €14 million in milestones to fund the work through Phase Ib.
Alexion has the right to acquire the company along the way for an unspecified amount.
CP010 has been put through in vivo and in vitro tests in the lead-up to the clinic by Frank Baas, the chief scientific officer at Complement and a co-founder of the company. He’s partnered with Robert Jan Lamers and has some backing from unspecified investors.
Alexion has been reorganizing and refocusing in the wake of Ludwig Hantson’s arrival as CEO as the company looks to move beyond Soliris and its successor med in the pipeline.